Groupe Bruxelles Lambert SA - Company Profile
Powered by 
All the sales intelligence you need on Groupe Bruxelles Lambert SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Groupe Bruxelles Lambert SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Groupe Bruxelles Lambert SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Groupe Bruxelles Lambert SA (GBL) is a family-owned investment firm with a focus on identifying investment opportunities and managing its portfolio. The company's main activities include investing in sector-leading global companies and alternative assets, as well as exerting influence on the companies in which it invests. GBL operates in various sectors such as minerals, bicycles, diagnostics, and ophthalmology services. The company's products and services cater to industries like healthcare, digital, consumer goods, and industry, focusing on companies that can deliver meaningful and sustained growth. GBL partners with sector companies and invests in both listed and private companies, leveraging its network and sourcing capabilities. The company has a presence in the Americas, Asia, and Europe. GBL is headquartered in Brussels, Belgium.
Headquarters
Belgium
Address
Avenue Marnix 24, Bruxelles, Bruxelles-Capitale , 1000
Website
www.gbl.com/fr
Telephone
32 2 2891786
No of Employees
83
Industry
Financial Services
Ticker Symbol & Exchange
GBLB (EBR)
Revenue (2024)
$7.1B
-5.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-573.1%
(2024 vs 2023)
Market Cap*
$11.8B
Net Profit Margin (2024)
XYZ
-599.0%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Services | Brands |
|---|---|
| Portfolio Management Services | GBL |
| Alternative Assets | |
| Investment Management |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Plans/Strategy | In May, the company and CVC Capital Partners announced their plans to acquire Recordati, a pharmaceutical company. |
| 2026 | Contracts/Agreements | In April, the company entered into an agreement to acquire BUKO Group from Equistone Partners and the Founding Family. |
| 2026 | Contracts/Agreements | In February, the company signed an agreement to acquire a 45% stake in Rayner, a manufacturer of intraocular lenses and related products. |
Competitor Comparison
| Key Parameters | Groupe Bruxelles Lambert SA | Investor AB | Wendel SE | AB Industrivarden | Kinnevik AB |
|---|---|---|---|---|---|
| Headquarters | Belgium | Sweden | France | Sweden | Sweden |
| City | Bruxelles | Stockholm | Paris | Stockholm | Stockholm |
| State/Province | Bruxelles-Capitale | - | Ile-de-France | Stockholm | Stockholm |
| No. of Employees | 83 | 20,915 | 88,439 | 15 | 35 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ian Gallienne | Chairman | Executive Board | 2025 | 55 |
| Johannes Huth | Managing Director; Director | Executive Board | 2025 | 66 |
| Xavier Likin | Chief Financial Officer | Senior Management | 2017 | 58 |
| Priscilla Maters | Compliance Officer; General Counsel; General Secretary | Senior Management | 2021 | 48 |
| Paul Desmarais III | Director | Non Executive Board | 2014 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer